{"title":"华语非酒精性脂肪肝患者及其医护人员的耻辱感","authors":"Zobair M. Younossi, Maria Stepanova","doi":"10.1016/j.jhep.2024.10.026","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Abbreviations</h2>Metabolic dysfunction-associated steatotic liver disease (MASLD), non-alcoholic fatty liver disease (NAFLD), type 2 diabetes (T2D), metabolic dysfunction-associated fatty liver disease (MAFLD), non-alcoholic steatohepatitis (NASH), metabolic dysfunction-associated steatohepatitis (MASH)”<u>Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a very common liver disease in the general population with an especially high</u></section></section><section><section><h2>Uncited reference</h2>2.; 3.; 4.; 15..</section></section><section><section><h2>Funding</h2>No funding was received for this work.</section></section><section><section><h2>Declaration of Competing Interest</h2>ZMY has received research funding and/or serve as consultant to Intercept, CymaBay, Boehringer Ingelheim, BMS, GSK, NovoNordisk, Ipsen, AstraZeneca, Siemens, Madridgal, Merck and Abbott</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":26.8000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Stigma Among Chinese Speaking Patients with Non-alcoholic Fatty Liver Disease and Their Providers\",\"authors\":\"Zobair M. Younossi, Maria Stepanova\",\"doi\":\"10.1016/j.jhep.2024.10.026\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h2>Section snippets</h2><section><section><h2>Abbreviations</h2>Metabolic dysfunction-associated steatotic liver disease (MASLD), non-alcoholic fatty liver disease (NAFLD), type 2 diabetes (T2D), metabolic dysfunction-associated fatty liver disease (MAFLD), non-alcoholic steatohepatitis (NASH), metabolic dysfunction-associated steatohepatitis (MASH)”<u>Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a very common liver disease in the general population with an especially high</u></section></section><section><section><h2>Uncited reference</h2>2.; 3.; 4.; 15..</section></section><section><section><h2>Funding</h2>No funding was received for this work.</section></section><section><section><h2>Declaration of Competing Interest</h2>ZMY has received research funding and/or serve as consultant to Intercept, CymaBay, Boehringer Ingelheim, BMS, GSK, NovoNordisk, Ipsen, AstraZeneca, Siemens, Madridgal, Merck and Abbott</section></section>\",\"PeriodicalId\":15888,\"journal\":{\"name\":\"Journal of Hepatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":26.8000,\"publicationDate\":\"2024-10-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jhep.2024.10.026\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2024.10.026","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Stigma Among Chinese Speaking Patients with Non-alcoholic Fatty Liver Disease and Their Providers
Section snippets
Abbreviations
Metabolic dysfunction-associated steatotic liver disease (MASLD), non-alcoholic fatty liver disease (NAFLD), type 2 diabetes (T2D), metabolic dysfunction-associated fatty liver disease (MAFLD), non-alcoholic steatohepatitis (NASH), metabolic dysfunction-associated steatohepatitis (MASH)”Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a very common liver disease in the general population with an especially high
Uncited reference
2.; 3.; 4.; 15..
Funding
No funding was received for this work.
Declaration of Competing Interest
ZMY has received research funding and/or serve as consultant to Intercept, CymaBay, Boehringer Ingelheim, BMS, GSK, NovoNordisk, Ipsen, AstraZeneca, Siemens, Madridgal, Merck and Abbott
期刊介绍:
The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.